Treatment options for non-motor symptoms in late-stage Parkinson's disease

Bibliography

• Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45
   PubMed Web of Science ®Google Scholar
• Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55:S2-6
   PubMed Web of Science ®Google Scholar
• Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-8
   PubMed Web of Science ®Google Scholar
• Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S23-9
   PubMed Web of Science ®Google Scholar
• Clarke CE. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Psychiatry 1993;56:690-3
   PubMedGoogle Scholar
• Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998;44:S1-9
   Google Scholar
• Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-50
   PubMed Web of Science ®Google Scholar
• Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677-92
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-89
   PubMed Web of Science ®Google Scholar
• Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006;6:1695-705
   PubMedGoogle Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-61
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating Parkinson's disease patients. Neurology 2000;55:789-94
   PubMed Web of Science ®Google Scholar
• Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-7
   PubMed Web of Science ®Google Scholar
• Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-4
   PubMed Web of Science ®Google Scholar
• Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-91
   PubMed Web of Science ®Google Scholar
• Bilal L, Tsai C, Gasper JJ, Ndlela JC. Parkinsonism with intramuscular ziprasidone. Am J Psychiatry 2005;162:2392-3
   PubMedGoogle Scholar
• Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28:111-4
   PubMed Web of Science ®Google Scholar
• Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-81
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27:4-5
   PubMed Web of Science ®Google Scholar
• Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21:1538-9
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63
   PubMed Web of Science ®Google Scholar
• Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95
   PubMed Web of Science ®Google Scholar
• Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57
   PubMed Web of Science ®Google Scholar
• Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5
   PubMed Web of Science ®Google Scholar
• Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust NZ J Psychiatry 2004;38:915-22
   PubMed Web of Science ®Google Scholar
• Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. Am J Psychiatry 2004;161:1501
   PubMed Web of Science ®Google Scholar
• Elias TJ, Bannister KM, Clarkson AR, et al. Clozapine-induced acute interstitial nephritis. Lancet 1999;354:1180-1
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000;355:1155-6
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-8
   PubMed Web of Science ®Google Scholar
• Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004;19:871-84
   PubMed Web of Science ®Google Scholar
• Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98
   PubMed Web of Science ®Google Scholar
• Deane KH, Jones D, Playford ED, et al. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2001:CD002817
   PubMedGoogle Scholar
• Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82
   PubMed Web of Science ®Google Scholar
• Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134-40
   PubMed Web of Science ®Google Scholar
• Protas EJ, Mitchell K, Williams A, et al. Gait and step training to reduce falls in Parkinson's disease. NeuroRehabilitation 2005;20:183-90
   PubMed Web of Science ®Google Scholar
• Deane KH, Ellis-Hill C, Playford ED, et al. Occupational therapy for patients with Parkinson's disease. Cochrane Database Syst Rev 2001:CD002813
   Google Scholar
• Sato Y, Iwamoto J, Kanoko T, Satoh K. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924-9
   PubMedGoogle Scholar
• Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911-5
   PubMed Web of Science ®Google Scholar
• Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64-8
   PubMedGoogle Scholar
• Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006;21:1856-63
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-5
   PubMed Web of Science ®Google Scholar
• Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005;331:1453-6
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:822-35
   PubMed Web of Science ®Google Scholar
• Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-41
   PubMedGoogle Scholar
• Vaddadi G, Lambert E, Corcoran SJ, Esler MD. Postural syncope: mechanisms and management. Med J Aust 2007;187:299-304
   PubMed Web of Science ®Google Scholar
• Stocchi F. Gastrointestinal, urological. and sleep problems in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 251-75
   Google Scholar
• Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986;19:283-7
   PubMed Web of Science ®Google Scholar
• Deane KH, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson's disease. Mov Disord 2002;17:984-91
   PubMed Web of Science ®Google Scholar
• Deane KH, Whurr R, Clarke CE, et al. Non-pharmacological therapies for dysphagia in Parkinson's disease. Cochrane Database Syst Rev 2001:CD002816
   Google Scholar
• Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-7
   PubMed Web of Science ®Google Scholar
• Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81
   PubMed Web of Science ®Google Scholar
• Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7
   PubMedGoogle Scholar
• Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999;67:697
   PubMed Web of Science ®Google Scholar
• Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7:329-32
   PubMed Web of Science ®Google Scholar
• Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40
   PubMed Web of Science ®Google Scholar
• Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007;22:2268-73
   PubMed Web of Science ®Google Scholar
• Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007;30:52-4
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44
   PubMed Web of Science ®Google Scholar
• Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45
   PubMed Web of Science ®Google Scholar
• Stocchi F. Depression, psychosis, and cognitive dysfunction in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 237-50
   Google Scholar
• Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol 2005;4:423-31
   PubMedGoogle Scholar
• Cooper IS. Neurosurgical treatment of the dyskinesias. Clin Neurosurg 1977;24:367-90
   PubMedGoogle Scholar
• Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65:355-9
   PubMed Web of Science ®Google Scholar
• Kwak YT, Han IW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222
   PubMedGoogle Scholar
• Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140-2
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord 1986;1:45-9
   PubMedGoogle Scholar
• Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003;48:829-38
   PubMed Web of Science ®Google Scholar
• Van Der Windt DA, Koes BW, Deville W, et al. Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ 1998;317:1292-6
   PubMedGoogle Scholar
• Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-6
   PubMed Web of Science ®Google Scholar
• Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope – update 2004. Europace 2004;6:467-537
   PubMed Web of Science ®Google Scholar
• Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-9
   PubMed Web of Science ®Google Scholar
• Schroeder C, Bush VE, Norcliffe LJ, et al. Water drinking acutely improves orthostatic tolerance in healthy subjects. Circulation 2002;106:2806-11
   PubMed Web of Science ®Google Scholar
• Jordan J, Shannon JR, Grogan E, et al. A potent pressor response elicited by drinking water. Lancet 1999;353:723
   PubMed Web of Science ®Google Scholar
• Naschitz JE, Slobodin G, Elias N, Rosner I. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Postgrad Med J 2006;82:246-53
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76
   PubMed Web of Science ®Google Scholar
• Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-8
   PubMed Web of Science ®Google Scholar
• Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989;39:1309-14
   PubMed Web of Science ®Google Scholar
• Calne DB, Shaw DG, Spiers AS, Stern GM. Swallowing in parkinsonism. Br J Radiol 1970;43:456-7
   PubMedGoogle Scholar
• Bramble MG, Cunliffe J, Dellipiani AW. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease. J Neurol Neurosurg Psychiatry 1978;41:709-12
   PubMedGoogle Scholar
• Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989;4:47-52
   PubMedGoogle Scholar
• Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980;27:414-20
   PubMed Web of Science ®Google Scholar
• Leon AS, Spiegel HE. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972;12:263-7
   PubMedGoogle Scholar
• Abrams WB, Coutinho CB, Leon AS, Spiegel HE. Absorption and metabolism of levodopa. JAMA 1971;218:1912-4
   PubMed Web of Science ®Google Scholar
• Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80
   PubMed Web of Science ®Google Scholar
• Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989;46:1061-4
   PubMedGoogle Scholar
• Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3
   PubMed Web of Science ®Google Scholar